Relationship of molecular structure to the mechanism of lysophospholipid-induced smooth muscle cell proliferation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 279, Issue 4 48-4, 2000, Pages

  Chai, Yuh Cherng ^a   Binion, David G ^a   Chisolm, Guy M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Basic fibroblast growth factor; Lysophosphatidic acid; Lysophosphatidylcholine; Platelet activating factor; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; LYSOPHOSPHOLIPID; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; DNA SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

EID: 0033680490     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.2000.279.4.h1830     Document Type: Article

References (47)

1. Angiotensin increases cytosolic free calcium in cultured vascular smooth muscle cells
2. Oxidized low-density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells: Evidence for release of FGF-2
3. Role of oxidized human plasma low-density lipoproteins in atherosclerosis: Effects on smooth muscle cell proliferation
4. 2+ influx, enhanced DNA synthesis and cytotoxicity in cultured vascular smooth muscle cells
5. Induction of DNA synthesis by a single transient mechanical stimulus of human vascular smooth muscle cells: Role of fibroblast growth factor- 2
6. The effects of oxidized lipids and lipoproteins on arterial growth, remodeling and restenosis
7. Oxidized lipoproteins and atherosclerosis
8. Lysophosphatidylcholine regulates cationic amino acid transport and metabolism in vascular smooth muscle cells. Role in polyamine biosynthesis
9. Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity
10. Molecular cloning of a high-affinity receptor for the growth factor-like lipid mediator lysophosphatidic acid from Xenopus oocytes
11. Vzg-1 encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex
12. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells
13. 2+-mobilizing stimulus for fibroblasts. Evidence for an extracellular site of action
14. Augmentation of DNA synthesis in guinea pig bone marrow cells by platelet-activating factor (PAF)
15. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins
16. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells
17. Effect of α-tocopherol on restenosis after angioplasty in a model of experimental atherosclerosis
18. Platelet-activating factor mediates an autocrine proliferative loop in the endometrial adenocarcinoma cell line HEC- 1A
19. Low-density lipoprotein cytotoxicity induced by free radical peroxidation of lipid
20. Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein
21. Comparative toxicity of oxidatively modified low-density lipoprotein and lysophosphatidylcholine in cultured vascular endothelial cells
22. Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes
23. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (lysoPC) in ovarian cancer patients
24. 2 activity of apoprotein B-100
25. Lysophosphatidylcholine concentration and metabolism in aortic intima plus inner media: Effect of nutritionally induced atherosclerosis
26. Lysophosphatidylcholine: A chemotactic factor for human monocytes and its potential role in atherogenesis
27. Plafibride treatment and serum lipids in hyperlipoproteinemias
28. Modification of low-density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low-density lipoprotein phospholipids
29. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge heart antioxidant study
30. Active oxygen species and lysophosphatidylcholine are involved in oxidized low-density lipoprotein activation of smooth muscle cell DNA synthesis
31. Receptor-independent signalling by PAF in vascular smooth muscle cells
32. Interaction of platelet-activating factor with endothelial and vascular smooth muscle cells in coculture
33. An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma
34. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and probucol study group
35. The binding of lysophospholipids to rat liver fatty acid-binding protein and albumin
36. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta
37. Lysophosphatidate-induced cell proliferation: Identification and dissection of signaling pathways mediated by G proteins
38. Mitogenic action of lysophosphatidic acid and phosphatidic acid on fibroblasts. Dependence on acyl-chain length and inhibition by suramin
39. Cytolytic and membrane-perturbing properties of lysophosphatidylcholine
40. Elevated expression of basic fibroblast growth factor in an immortalized rabbit smooth muscle cell line
41. Role of oxidized low-density lipoprotein in atherogenesis
42. Lysophosphatidylcholine stimulates the release of arachidonic acid in human endothelial cells
43. Lysophosphatidylcholine stimulates MAP kinase activity in rat vascular smooth muscle cells
44. Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man
45. The bioactive phospholipid, lysophosphatidylcholine, induces cellular effects via G protein-dependent activation of adenylyl cyclase
46. Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine
47. Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidylcholine